2014
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
Lu G, Zhang Q, Huang Y, Song J, Tomaino R, Ehrenberger T, Lim E, Liu W, Bronson RT, Bowden M, Brock J, Krop IE, Dillon DA, Gygi SP, Mills GB, Richardson AL, Signoretti S, Yaffe MB, Kaelin WG. Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. Cancer Cell 2014, 26: 222-234. PMID: 25117710, PMCID: PMC4169234, DOI: 10.1016/j.ccr.2014.06.026.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsBinding SitesFemaleHCT116 CellsHEK293 CellsHumansMiceMice, Inbred NODMice, SCIDMolecular Sequence DataNeoplasm TransplantationPhosphorylationProtein BindingProto-Oncogene Protein c-ets-1Proto-Oncogene Protein c-ets-2Src-Family KinasesTriple Negative Breast NeoplasmsTumor BurdenUbiquitinationUbiquitin-Protein LigasesConceptsSrc family kinasesFamily kinasesTumor suppressorPhosphorylation of ETS1Ubiquitin ligase componentTumor suppressor proteinAnchorage-independent growthNeighboring tyrosine residueCOP1 substratesRegulatory phosphorylationSpecific serineThreonine residuesSrc familySuppressor proteinTyrosine residuesETS1Breast cancer cellsPhosphorylationCancer cellsNeoplastic growthKinaseSuppressorProteinOncoproteinResidues
2010
Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
Mayer EL, Krop IE. Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies. Clinical Cancer Research 2010, 16: 3526-3532. PMID: 20634194, DOI: 10.1158/1078-0432.ccr-09-1834.Peer-Reviewed Original ResearchConceptsMultiple solid tumor typesVascular endothelial growth factor receptorEndothelial growth factor receptorEarly phase trialsSolid tumor typesMultiple human malignanciesTargeting SrcEndocrine therapyGrowth factor receptorCombination regimensOngoing trialsFuture trialsSolid malignanciesProstate cancerBreast cancerEstrogen receptorPreclinical studiesAntitumor effectsTumor typesAngiogenesis inhibitorsCell-signaling pathwaysInhibitor dasatinibInvestigation of combinationsHuman malignanciesModest activity